Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation

[1]  J. Cerhan,et al.  Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  O. Tournilhac,et al.  Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization , 2008, Leukemia.

[3]  P. Gobbi,et al.  Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study , 2008, Haematologica.

[4]  P. Chiusolo,et al.  Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre‐transplant therapy , 2007, Clinical transplantation.

[5]  L. Rybicki,et al.  Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Mufti,et al.  High incidence of therapy‐related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders , 2006, British journal of haematology.

[7]  S. Pileri,et al.  Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Matthews,et al.  Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine , 2004, Leukemia.

[9]  John M Bennett,et al.  Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Lois Shepherd,et al.  Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Kirchner,et al.  Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. , 2002, Blood.

[12]  L. Rybicki,et al.  Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up , 2002, Bone Marrow Transplantation.

[13]  W. Plunkett,et al.  DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Mehta,et al.  Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma , 2000, British Journal of Cancer.

[15]  M. Goormastic,et al.  Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma , 2000, Bone Marrow Transplantation.

[16]  T. Lister,et al.  Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Martinelli,et al.  Fludarabine‐containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients , 1999, British journal of haematology.

[18]  B. Overmoyer,et al.  Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial , 1998, Bone Marrow Transplantation.

[19]  P. Mclaughlin,et al.  Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[21]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[22]  C. Tam,et al.  Treatment-related myelodysplasia following fludarabine combination chemotherapy. , 2006, Haematologica.

[23]  L. Lilly,et al.  Liver transplantation for HBV and management of reinfection , 2005 .

[24]  P. Feugier,et al.  Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. , 2004, Blood.

[25]  U. Germing,et al.  Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. , 2001, Leukemia research.